AN AFFILIATE OF SUN EUROPEAN PARTNERS, LLP ENTERS INTO AN AGREEMENT TO ACQUIRE NEXTPHARMA TECHNOLOGIES HOLDING LTD, THE GLOBAL PHARMACEUTICAL OUTSOURCING PARTNER
11 January 2011
LONDON, UK Sun European Partners, LLP ("Sun European Partners"), the
European adviser to Sun Capital Partners, Inc., announces that one of its affiliates
has entered into an agreement to acquire NextPharma Technologies Holding Ltd
(“NextPharma”), a global provider of contract manufacturing, product development,
clinical trials and logistics services to the pharmaceutical and biotechnology industry. Terms of the transaction were not disclosed.
Headquartered in Surrey, UK, NextPharma offers a range of services spanning the
entire drug development, manufacturing and distribution supply chain. The company is a leading outsourcing partner to the pharmaceutical, biotech and healthcare industries with seven manufacturing facilities, seven product development centres and six temperature-controlled storage and distribution sites across Europe and the U.S. NextPharma supports more than 200 customers including leading blue chip pharmaceutical and biotech companies.
Bill Wedlake, CEO of NextPharma commented: “For many years we have worked
closely with our customers to develop a full range of integrated pharmaceutical
development, manufacturing and logistics services to provide flexibility and
confidence through high levels of quality and customer service. We are excited to
work with Sun European Partners to continue to grow the company and to expand
into innovative new technologies and markets.”
Matthias Gundlach, Vice President of Sun European Partners added: “The
pharmaceutical industry is increasingly using drug development and manufacturing
outsourcing. NextPharma, with its strong track record, reputation and state of the art facilities, is well positioned to capitalise on these trends. We see significant
opportunity to grow the business both organically and by acquisitions and look
forward to working with management to achieve this potential.”
- Ends -
About Sun European Partners, LLP
Sun European Partners, LLP is the European adviser to Sun Capital Partners, Inc.,a leading U.S.-based private investment firm focused on leveraged buyouts, equity, debt, and other investments in market-leading companies that can benefit from its in–house operating professionals and experience. Affiliates of Sun Capital Partners, Inc. have invested in more than 250 companies worldwide with combined sales in excess of $40 billion since the inception of Sun Capital Partners, Inc. in the U.S. in 1995. Sun Capital Partners, Inc. has offices in Boca Raton, Los Angeles, and New York, as well as affiliates with offices in London, Paris, Frankfurt, Luxembourg, Shanghai and Shenzhen.
For more information, please visit www.SunEuropeanPartners.com.
Maitland +44(0)20 7379 5151
Anthony Silverman
Rowan Brown
Contact NextPharma
Franck Latrille
Chief Executive Officer
NextPharma Technologies Holding Limited
Tel +44 (0) 1483 479 120
Notes to Editors:
About NextPharma
NextPharma Technologies, headquartered in the UK and founded in 2000, is a world class outsourcing partner to the pharmaceutical and biotechnology industry.
We offer a full range of services from early phase product development, through clinical trial packaging (Phases I through III) to high volume commercial manufacturing. We are a world leader in lyophilization, sterile fill finish and pellet technologies and in specialist product manufacturing including cytotoxics, hormones, penicillins, cephalosporins and controlled drugs. Our sterile development and production offers a full range of drug delivery technologies including pre-filled syringes, vials and ampoules. Additionally we have significant expertise in paediatric drug formulation, development and manufacture.
We operate globally with seven product development centres, seven manufacturing plants and six temperature controlled storage and distribution sites across Europe and North America, supplying customers in North America, Europe and Japan.
.
We have 1,200 employees dedicated to serving over 200 customers world wide and a customer base, which includes many of the world’s leading pharmaceutical, specialty pharma and biotech companies.
We have a proven track record in almost all pharmaceutical technologies and product forms and in addition to the specialist areas above have capabilities in solids, semi-solids, liquids, sprays and dry dosage form technologies.
All of our sites are either FDA inspected, in the process of upgrade for inspection or targeted for upgrade for inspection.

